Catalyst Pharmaceuticals, Inc. $CPRX Stock Holdings Increased by Walleye Capital LLC

Walleye Capital LLC increased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 253.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 71,149 shares of the biopharmaceutical company’s stock after purchasing an additional 51,010 shares during the quarter. Walleye Capital LLC owned approximately 0.06% of Catalyst Pharmaceuticals worth $1,762,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CPRX. State Street Corp boosted its stake in shares of Catalyst Pharmaceuticals by 7.8% during the 4th quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock valued at $161,224,000 after buying an additional 502,235 shares during the period. Deerfield Management Company L.P. grew its holdings in shares of Catalyst Pharmaceuticals by 72.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after acquiring an additional 2,095,291 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Catalyst Pharmaceuticals by 14.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after acquiring an additional 433,318 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after acquiring an additional 333,100 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Catalyst Pharmaceuticals by 59.1% during the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after acquiring an additional 1,089,775 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CPRX. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $35.00 to $31.50 in a report on Friday, May 8th. Finally, Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $31.49 on Friday. The company has a market capitalization of $3.86 billion, a P/E ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. The firm’s fifty day simple moving average is $31.38 and its 200-day simple moving average is $27.27. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $32.56.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).